Ticagrelor Dosing for Acute Coronary Syndrome
Yes, the dosing schedule of 180 mg stat, then 90 mg after 6-12 hours, followed by 90 mg twice daily is correct for acute coronary syndrome. 1, 2
Loading and Maintenance Dose Schedule
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines and FDA labeling provide clear dosing instructions:
- Loading dose: 180 mg orally as a single dose at presentation
- First maintenance dose: 90 mg administered 6 to 12 hours after the loading dose (not immediately after)
- Ongoing maintenance: 90 mg twice daily for the first year after ACS
- After one year: Consider reducing to 60 mg twice daily 1, 2
Important Timing Clarification
The critical detail is the 6-12 hour gap between the loading dose and first maintenance dose. This is explicitly stated in both the 2025 guidelines and FDA labeling 1, 2. Your proposed schedule of "90 mg after 12 hours" aligns with the upper end of this recommended window and is appropriate.
Aspirin Co-Administration
Always use low-dose aspirin (75-100 mg daily) with ticagrelor, never higher doses. 1
- Post hoc analysis from the PLATO trial demonstrated that aspirin doses >100 mg daily may reduce ticagrelor effectiveness 1
- Initial loading dose of aspirin should be 162-325 mg (chewed for faster onset), followed by 75-100 mg daily maintenance 1
Preference Over Other P2Y12 Inhibitors
Ticagrelor or prasugrel are strongly preferred over clopidogrel in ACS patients undergoing PCI (Class 1, Level A recommendation) 1. The guidelines explicitly state ticagrelor should be administered to reduce major adverse cardiovascular events (MACE) and stent thrombosis 1.
Duration of Therapy
- First 12 months: Dual antiplatelet therapy (DAPT) with aspirin + ticagrelor 90 mg twice daily is the default strategy 3
- After 1 year: Consider transitioning to ticagrelor 60 mg twice daily 2
- Early aspirin discontinuation: In patients who tolerate DAPT well, transition to ticagrelor monotherapy at 1 month post-PCI is reasonable to reduce bleeding risk 3
Key Safety Considerations
Do not use ticagrelor in patients with:
- Active pathological bleeding
- History of intracranial hemorrhage
- Planned urgent CABG 2
Common pitfall: Approximately 14-21% of patients develop dyspnea with ticagrelor, usually mild-to-moderate and often resolving with continued treatment 2. This leads to discontinuation in only 0.9-4.3% of patients depending on the population.
Special Populations
For patients >75 years old, recent evidence suggests ticagrelor 60 mg twice daily provides similar platelet inhibition to 90 mg twice daily 4, though the standard 90 mg dose remains guideline-recommended for the first year post-ACS.